TY - JOUR
T1 - International neuroblastoma risk group consortium
T2 - a model of networking for rare cancers
AU - Cohn, Susan L.
AU - London, Wendy B.
AU - Schleiermacher, Gudrun
AU - Moreno, Lucas
AU - Ambros, Inge M.
AU - Ambros, Peter F.
AU - Bagatell, Rochelle
AU - Popovic, Maja Beck
AU - Beiske, Klaus Hermann
AU - Berthold, Frank
AU - Birz, Suzi
AU - Brisse, Hervé J.
AU - Brodeur, Garrett M.
AU - Brock, Penelope R.
AU - Burchill, Susan
AU - Eggert, Angelika
AU - Federico, Sara M.
AU - Fischer, Matthias
AU - Furner, Brian T.
AU - Hero, Barbara
AU - Machin, David
AU - Kamijo, Takehiko
AU - Matthay, Katherine K.
AU - Nakagawara, Akira
AU - Naranjo, Arlene
AU - Pötschger, Ulrike
AU - Valteau-Couanet, Dominique
AU - Watkins, Michael T.
AU - Irwin, Meredith S.
AU - Volchenboum, Samuel L.
AU - Park, Julie R.
AU - Pearson, Andrew D.J.
N1 - Publisher Copyright:
© The Author(s) 2025. Published by Oxford University Press.
PY - 2026/4
Y1 - 2026/4
N2 - It is critical to share knowledge and harmonize approaches to optimize progress in rare cancers. The International Neuroblastoma Risk Group (INRG) Task Force was formed by the 4 major neuroblastoma cooperative groups in 2004 to achieve this goal. Strategies developed for neuroblastoma are an exemplar for other rare malignancies. Data from an initial cohort of 8800 patients were transferred to the INRG Data Commons, and a data-sharing model was developed. Currently, information on more than 25 000 patients is available to the research community. The INRG staging and risk classification systems have led to harmonized approaches for therapeutic groupings. INRG consensus manuscripts have led to uniform criteria for classifying biological data, evaluating the extent of disease, and defining treatment response. More than 40 INRG research studies have been performed by investigators from around the world, including analyses of rare patients, which would not otherwise be possible. The success of this approach for neuroblastoma has been leveraged to create the Pediatric Cancer Data Commons and the Data for the Common Good. Efforts to enrich the INRG Commons with additional genomic and biomarker data, extracted electronic health records, and digital medical images are ongoing. The international networking model developed by the INRG Task Force has led to new research discoveries and progress in neuroblastoma. The approach has now been applied to 16 other cancers and conditions, including rhabdomyosarcoma, germ cell tumor, Lynch syndrome, and cancer predisposition. This framework of international collaboration and data sharing serves as a model for advancing rare adult malignancies.
AB - It is critical to share knowledge and harmonize approaches to optimize progress in rare cancers. The International Neuroblastoma Risk Group (INRG) Task Force was formed by the 4 major neuroblastoma cooperative groups in 2004 to achieve this goal. Strategies developed for neuroblastoma are an exemplar for other rare malignancies. Data from an initial cohort of 8800 patients were transferred to the INRG Data Commons, and a data-sharing model was developed. Currently, information on more than 25 000 patients is available to the research community. The INRG staging and risk classification systems have led to harmonized approaches for therapeutic groupings. INRG consensus manuscripts have led to uniform criteria for classifying biological data, evaluating the extent of disease, and defining treatment response. More than 40 INRG research studies have been performed by investigators from around the world, including analyses of rare patients, which would not otherwise be possible. The success of this approach for neuroblastoma has been leveraged to create the Pediatric Cancer Data Commons and the Data for the Common Good. Efforts to enrich the INRG Commons with additional genomic and biomarker data, extracted electronic health records, and digital medical images are ongoing. The international networking model developed by the INRG Task Force has led to new research discoveries and progress in neuroblastoma. The approach has now been applied to 16 other cancers and conditions, including rhabdomyosarcoma, germ cell tumor, Lynch syndrome, and cancer predisposition. This framework of international collaboration and data sharing serves as a model for advancing rare adult malignancies.
UR - https://www.scopus.com/pages/publications/105035415421
U2 - 10.1093/jnci/djaf242
DO - 10.1093/jnci/djaf242
M3 - Comment/debate
C2 - 40854111
AN - SCOPUS:105035415421
SN - 0027-8874
VL - 118
SP - 579
EP - 588
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 4
ER -